AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2036277
Drug: Lornoxicam 2
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 2 mg
Trial: 7665721
Drug: Lornoxicam 4
RxNorm normalized name: lornoxicam 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 4 mg
Trial: 29982720
Drug: Treatment adjustment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment adjustment not in agreement with TTT strategy
Trial: 26642907
Drug: Pharmacogenetic-guided warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic-guided warfarin dosing algorithm
Trial: 12631126
Drug: Eprosartan (E)
DrugBank: Eprosartan (DB00876)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eprosartan (E) 600 mg/day PO for seven days
Trial: 9032777
Drug: 0.03 mg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg/h cortisol infusion
Trial: 9032777
Drug: 0.06 mg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg/kg/h cortisol infusion
Trial: 9032777
Drug: Placebo condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo condition (placebo tablets and normal saline infusion)
Trial: 27687343
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of remifentanil (HR) group
Trial: 8942357
Drug: High-energy-protein supplement
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy-protein supplement given immediately after rehydration
Trial: 8942357
Drug: High-energy-protein supplement
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy-protein supplement given 2 weeks after presentation
Trial: 2057036
Drug: 16-hour nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16-hour nicotine patch (15 +/- 3.5 mg of nicotine in 16 hours)
Trial: 3914473
Drug: Cefotaxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1 gram preoperative dose)
Trial: 3914473
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 gram preoperative dose and four 2 gram postoperative doses)
Trial: 10695838
Drug: Psychopharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychopharmacological treatment
Trial: 22344555
Drug: Pidotimod 800
RxNorm normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod 800 mg
Trial: 16185216
Drug: Five-Day Plan
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Five-Day Plan (FDP) - a behavioural group-based treatment programme involving five consecutive evening sessions.
Trial: 18547294
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg.kg(‐1))
Trial: 1671795
Drug: Retinol palmitate
RxNorm normalized name: Retinol palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinol palmitate (300,000 IU daily for at least 12 months)
Trial: 6361986
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 50-100 mg/kg/day
Trial: 26390335
Drug: Mindfulness-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based therapy for insomnia (MBTI)
Trial: 17617790
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI)
Trial: 23991670
Drug: GW870086 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW870086 (1 mg, once-daily)
Trial: 21632199
Drug: Treatment setting
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment setting control
Trial: 18501783
Drug: Fenofibrate (160-mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (160-mg/d tablet)
Trial: 8927195
Drug: Anti-stress therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-stress therapy
Trial: 1624155
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride capsules
Trial: 368231
Drug: Glucose electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose electrolyte solution
Trial: 1624155
Drug: Glucose polymer
RxNorm normalized name: glucose polymers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose polymer solution
Trial: 12077570
Drug: Adenosine treatment
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine treatment
Trial: 8545744
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 2,400 mg of hypoxoside (4 capsules 3 times daily for 11 days)
Trial: 2253931
Drug: Lactitol (36.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactitol (36.3 g +/- 5 daily)
Trial: 2253931
Drug: Lactulose (38.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (38.2 g +/- 19 daily)
Trial: 30910563
Drug: Usual upper
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual upper limb therapy 5 days a week for 5 weeks
Trial: 26144895
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg HB vaccine in Group C
Trial: 22509319
Drug: MTZ-Clind (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTZ-Clind (oral metronidazole 400 mg bid + 2% vaginal clindamycin-cream)
Trial: 22509319
Drug: MTZ-Prob (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTZ-Prob (oral metronidazole 400 mg bid + Lactobacillus acidophilus vaginal-probiotic)
Trial: 22509319
Drug: MTZ-Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTZ-Placebo (oral metronidazole 400 mg bid + placebo)
Trial: 15385356
Drug: Cisatracurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.2 mg/kg based on real body weight (RBW) in Group I (n = 10)
Trial: 2337059
Drug: Overall Olsalazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall Olsalazine treatment
Trial: 10328033
Drug: 720 mg
RxNorm normalized name: pancreatin 720 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 720 mg trimethoprim plus 3,600 mg sulfamethoxazole
Trial: 10328033
Drug: 3.5 g
RxNorm normalized name: Calcium 760 MG/3.5 GM Oral Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 g ampicillin plus 1 g probenecid
Trial: 10375203
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BAP levels and percent BAP change at 6 months
Trial: 6130292
Drug: Naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone treatment (oral and intravenous)
Trial: 6130292
Drug: Control (large
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (large daily doses of laxatives and additional suppositories and enemas)
Trial: 3515468
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g or 2 g once daily for 7-12 days)
Trial: 25560155
Drug: Isotonic fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic fluid (0.9% NaCl solution in 5% dextrose)
Trial: 21197498
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading (111 implants, 45 patients)
Trial: 21197498
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading (111 implants, 51 patients)
Trial: 21197498
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement with immediate function (group 1)
Trial: 21197498
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant placement with immediate function (group 2)
Trial: 21197498
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant placement with delayed function (group 3)
Trial: 21197498
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant placement with delayed function (group 4)
Trial: 21197498
Drug: Immediate function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate function implants
Trial: 18386572
Drug: Ningzhi Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ningzhi Capsule (NZC) 5 tablets, 3 times a day for 6 months
Trial: 10092691
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg, 2 mg/puff, two puffs three times daily)
Trial: 10092691
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two puffs three times daily)
Trial: 1757042
Drug: 2% MK-507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% MK-507 (both formulations)
Trial: 6850464
Drug: BCG administered
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG administered orally in patients with resectable colon cancer
Trial: 6850464
Drug: BCG administered
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG administered intraperitoneally along with 5-fluorouracil for gastrointestinal cancer
Trial: 29621811
Drug: Injected Vitamin
RxNorm normalized name: vitamin A Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected Vitamin D (300,000 units in 1 cc)
Trial: 29621811
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo, 1 cc)
Trial: 24585722
Drug: Bevacizumab-pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab-pemetrexed (500 mg/m2)
Trial: 31780570
Drug: Bevacizumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (7.5 mg/kg)
Trial: 17522988
Drug: Methylphenidate, gradually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate, gradually increasing dosage over two weeks, followed by a similar two-week period of gradually diminishing dosage.
Trial: 12167115
Drug: Omeprazole (OMP)
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole (OMP) 20 mg once daily
Trial: 12167115
Drug: Famotidine (FAM)
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine (FAM) 20 mg twice daily
Trial: 8913711
Drug: Ondansetron (O)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron (O) 16 mg 3 times/day
Trial: 1905438
Drug: Dextrose 70%
RxNorm normalized name: DEXTROSE 70% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 70% injection (D70W) plus 15% amino acids for PN, 25-mL piggybacks, selected drugs added to the PN solution
Trial: 1905438
Drug: D70W plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D70W plus 10% amino acids, 50- or 100-mL piggybacks
Trial: 6393976
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg ASA/d
Trial: 6393976
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg ASA/d
Trial: 6393976
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ASA/d
Trial: 6393976
Drug: No ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ASA administration (control group)
Trial: 29204869
Drug: Valerate estradiol
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valerate estradiol 2 mg daily + dihydrogesterone 10 mg daily during luteal phase for 3 months before IVF
Trial: 16936304
Drug: No pre-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre-treatment
Trial: 27528065
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of plasminogen activator inhibitor-1 levels in fasting serum
Trial: 15763055
Drug: Toubiao Qingfei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toubiao Qingfei Decoction (TBQFD) + Western medicines
Trial: 18416072
Drug: Western medicines
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicines
Trial: 10442359
Drug: uracil/tegafur plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: uracil/tegafur plus oral calcium folinate (UFT)
Trial: 10442359
Drug: 5‐fluorouracil (5‐FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU) plus oral calcium folinate
Trial: 11015032
Drug: Promethazine 50
RxNorm normalized name: promethazine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 50 mg
Trial: 31376501
Drug: Parent-Child Interaction
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-Child Interaction Therapy with Emotion Development module (PCIT-ED)
Trial: 20183659
Drug: Standard Parent-Child
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Parent-Child Interaction Therapy (PCIT)
Trial: 25987078
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human endostatin (Endostar) 7.5 mg/m2, administered on postoperative day 89, 34 h/time, daily, for 14 weeks, total of 4 cycles
Trial: 25987078
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received postoperative complementary chemotherapy containing two-agent platinum protocol
Trial: 12024434
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C meningococcal conjugate vaccine
Trial: 11402115
Drug: L-dopa (300/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (300/75 mg/d)
Trial: 11402115
Drug: Pramipexole (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (1.5 mg/d)
Trial: 9431265
Drug: Electrical Nerve
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical Nerve Stimulation (ENS) therapy
Trial: 9431265
Drug: Electrical Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical Muscle Stimulation (EMS) therapy
Trial: 3900847
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (control group)
Trial: 30645864
Drug: Meat-containing canned
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat-containing canned food for enteral nutrition (240 ml, 2 portions daily for 14 days)
Trial: 19595605
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (conventional haemostatic fleece)
Trial: 17621464
Drug: Sequential pegylated
RxNorm normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pegylated interferon‐α2a plus delayed‐initiation tenofovir
Trial: 20811582
Drug: Opioid receptor
RxNorm normalized name: Opioid receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid receptor antagonist naloxone
Trial: 18267008
Drug: Conventional wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional wound therapy
Trial: 16835758
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated Oka strain varicella vaccine (Varilrix, GlaxoSmithKline Biologicals)
Trial: 12590879
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of hyaluronans
Trial: 10773631
Drug: Chlorhexidine varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine varnish (CV, Cervitec) containing 1% chlorhexidine and 1% thymol, treated every 3rd month for 3 years (12 treatments total)
Trial: 3436485
Drug: Ferritin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin (80 mg Fe3+)
Trial: 26875428
Drug: Heart rate-guided
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart rate-guided beta-blocker titration
Trial: 26875428
Drug: Beta-blocker uptitration
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker uptitration
Trial: 23541564
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus everolimus (5mg p.o. daily, after a step-wise dose-escalation starting from 2.5mg bid) for 12 weeks before surgery
Trial: 23541564
Drug: Paclitaxel alone
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel alone (80 mg/m(2) weekly for 12 weeks)
Trial: 18091017
Drug: 6.4% carbohydrate-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% carbohydrate-electrolyte (CHO-E) solution
Trial: 1461553
Drug: nimesulide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide (200 mg/day)
Trial: 27499311
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (40 mg/day women, 160 mg/day men) and high energy oral nutritional supplement (2108-2416 kJ/day)
Trial: 27499311
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication and low energy (142-191 kJ/day) 'placebo' oral nutritional supplementation
Trial: 27499311
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate and nutritional supplementation
Trial: 22434018
Drug: Hearing augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hearing augmentation device
Trial: 22434018
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hearing augmentation)
Trial: 20616774
Drug: Arginine-containing nutritional
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine-containing nutritional supplement (9 g per day until full PU healing)
Trial: 18534138
Drug: Insulin-blood cardioplegia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-blood cardioplegia (insulin and glucose added)
Trial: 18534138
Drug: Insulin-blood cardioplegia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-blood cardioplegia
Trial: 6449783
Drug: IK-6 (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IK-6 (combination of fenoterol and ipratropium bromide)
Trial: 31434537
Drug: Hand-Arm Bimanual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand-Arm Bimanual Intensive Therapy (H-HABIT)
Trial: 26163644
Drug: Arm I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm I: Irradiation of the whole pelvis to a dose of 50 Gy in 27 fractions, weekly cisplatin 40 mg/m2, HDR-ICBT after one week of completion of EBRT (7 Gy to point A for three insertions at one week intervals)
Trial: 26163644
Drug: Arm II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm II: Irradiation of the whole pelvis to a dose of 50 Gy in 27 fractions, cisplatin 20 mg/m2/day from D1‐5 and D24‐28, HDR-ICBT after 40Gy (7 Gy to point A for three insertions on days 23, 30, 37)
Trial: 24261438
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of paracetamol, chlorphenamine and phenylephrine (5 capsules per day for 48 to 72 hours)
Trial: 24261438
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 capsules per day for 48 to 72 hours)
Trial: 17449194
Drug: Low pretreatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low pretreatment EBV DNA (<1,500 copies/mL) and undetectable posttreatment EBV DNA (pre-L/post-U)
Trial: 17449194
Drug: High pretreatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High pretreatment EBV DNA (>=1,500 copies/mL) and undetectable posttreatment EBV DNA (pre-H/post-U)
Trial: 17449194
Drug: Low or
RxNorm normalized name: Milkflow oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low or high pretreatment EBV DNA and detectable posttreatment EBV DNA (pre-L or H/post-D)
Trial: 10224730
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CB)
Trial: 8063980
Drug: Brief psychodynamic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychodynamic therapy (PD)
Trial: 31782814
Drug: Budesonide (BD;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (BD; 256 μg) for 2 weeks